Preclinical, Clinical, and Over-the-Counter Postmarketing Experience with a New Vaginal Cup: Menstrual Collection

被引:42
作者
North, Barbara B. [1 ]
Oldham, Michael J. [2 ]
机构
[1] Indian Hlth Serv, Karuk Clin, Yreka, CA USA
[2] Univ Calif Irvine, Dept Community & Environm Med, Irvine, CA 92717 USA
关键词
PROTECTION; DIAPHRAGM; WOMEN;
D O I
10.1089/jwh.2009.1929
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Menstrual cups have been available for decades, but their use is limited by bulky design and the need for multiple sizes. The Softcup (R) (Instead, Inc., San Diego, CA) is a simple single-size disposable over-the-counter (OTC) menstrual cup that compresses to tampon shape to facilitate insertion and can be worn during coitus. This report describes preclinical evaluation, clinical testing, and postmarketing monitoring of the Softcup. Methods: Preclinical testing complied with U. S. Food and Drug Administration (FDA) guidelines and used standard United States Pharmacopoeia methodologies for assessment of potential toxicity. Clinical testing enrolled 406 women in seven U. S. centers. A detailed written questionnaire assessed safety, acceptability, and effectiveness for menstrual collection. Study safety parameters included pelvic examinations, Pap smears, colposcopy, urinalysis, vaginal pH, wet mounts, gram stain, and vaginal microflora cultures. Postmarketing surveillance of over 100 million Softcups has been conducted by the manufacturer and by the FDA Medwatch system. Results: No toxicity or mutagenicity was observed in preclinical evaluations. In clinical testing, after three cycles of cup use, 37% of subjects rated the cup as better than, 29% as worse than, and 34% as equal to pads or tampons. The cup was preferred for comfort, dryness, and less odor. Cups received lower ratings for disposal and convenience. Eighty-one percent of enrolled women were able to insert and remove their first cup using only written instructions. Use difficulties resulting in study discontinuations included cramping (1%), leakage (1%), and improper fit (3%). No safety parameters were adversely affected. No significant health risks were reported during postmarketing surveillance. Conclusions: These results demonstrate that a single-size vaginal device has no significant health risks and is acceptable to many women without the need for fitting or other medical services.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 27 条
  • [1] Duet® for menstrual protection: a feasibility study in Zimbabwe
    Averbach, Sarah
    Sahin-Hodoglugil, Nuriye
    Musara, Petina
    Chipato, Tsungai
    van der Straten, Ariane
    [J]. CONTRACEPTION, 2009, 79 (06) : 463 - 468
  • [2] Bharadwaj S., 2004, Menstrual Hygiene and Management in Developing Countries: Taking Stock
  • [3] Bright R, 2003, RETAINED MENSTRUAL T
  • [4] Chalmers L, 1937, U.S. Patent and Trademark Office, Patent No. 2089113
  • [5] MENSES CUP EVALUATION STUDY
    CHENG, M
    WILANSKY, D
    KUNG, R
    SHIME, J
    HANNAH, M
    [J]. FERTILITY AND STERILITY, 1995, 64 (03) : 661 - 663
  • [6] Delaney J., 1988, The curse: A cultural history of menstruation
  • [7] MENSTRUAL BLOOD-LOSS MEASUREMENT WITH GYNAESEAL
    GLEESON, N
    DEVITT, M
    BUGGY, F
    BONNAR, J
    [J]. AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1993, 33 (01) : 79 - 80
  • [8] Women's preferences for vaginal antimicrobial contraceptives.: V:: Attitudes of Brazilian women to the insertion of vaginal products
    Hardy, E
    de Pádua, KS
    Hebling, EM
    Osis, MJD
    Zaneveld, LJD
    [J]. CONTRACEPTION, 2003, 67 (05) : 391 - 395
  • [9] Hockert S, 1867, Catamenial Sack. U.S. Patent and Trademark Office, Patent No. 70843
  • [10] Houppert K., 1999, The curse: Confronting the last unmentionable taboo: Menstruation